Predictive Diagnostics: Global Strategic Business Report

Global Predictive Diagnostics Market to Reach $4.7 Billion by 2030

The global market for Predictive Diagnostics estimated at US$1.9 Billion in the year 2022, is projected to reach a revised size of US$4.7 Billion by 2030, growing at a CAGR of 12% over the analysis period 2022-2030.

The U.S. Market is Estimated at $561.1 Million, While China is Forecast to Grow at 11.1% CAGR

The Predictive Diagnostics market in the U.S. is estimated at US$561.1 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$804.8 Million by the year 2030 trailing a CAGR of 11.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.6% and 9.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 9.2% CAGR.

Select Competitors (Total 47 Featured) -

• Abbott Molecular
• Almac Group Ltd.
• Ambry Genetics Corp.
• BioGenex
• Epistem Ltd.
• Epistem Ltd.
• MDxHEALTH Inc.
• Myriad Genetics Inc.
• OPKO Health, Inc.
• Prometheus Laboratories Inc.
• QIAGEN N.V.

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year